1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges

"Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challengess” provides a detailed investigation of the market size, segmentation, key players, SWOT analysis, influential Government policies, and business and economic environments. The report is supported by over 265 tables & figures within 182 pages. The Chinese biopharmaceutical market is presented as follows:

- By Company (e.g., AMOYTOP BIOTECH, BEIJING CONTINENT PHARMACEUTICALS, FUSOGEN, SHANGHAI HUAGUAN BIOCHIP, SIBIONO GENETECH, ABBOTT, ROCHE, PFIZER, GSK, NOVARTIS)
- By Therapeutic Area (e.g., Anti-infective, Cancer, Diabetes, Dementia, Depression)

A wealth of financial information is provided including:
- Company financials, sales & revenue figures
- China GDP, economic growth, export (bulk drug, formulations) figures
- Indian health expenditure as a function of GDP
- Growth change figures of emerging and developing countries (India, Russia, China, Brazil)
- Economic growth figures of advanced economies (USA, UK, Germany, France, Italy, Spain, Japan, Canada)
- Projected figures of strategic emerging industry GDP percentage contribution

SWOT, Economic and Business Environment specifics include:

- Key strengths, weaknesses and threats influencing leading player position within the market
- Top Five Contract Pharmaceutical Export Markets of China
- Major players within China’s leading therapeutic markets (e.g., cancer, allergy, liver disease)
- Multinational penetration into the Chinese Pharma Market
- Comprehensive product portfolios, R&D activity and pipeline therapeutics
- M&A activity and future strategies of top Chinese pharmacos
- Economic indicators, trade policy, merchandise and commercial trade statistics
- Gross Domestic Product of China, historic and projection analysis
- Chinese economic outlook in comparison to advanced economies
- Three Tier ‘Pharmerging’ Markets with Potential for Significant Growth
- Prescription drug sales distribution channels in China
- Major biogeneric products in China

This report highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.

- Amoytop Biotech
- Active Pharmaceutical Products
- Beijing Continent Pharmaceuticals
- FusoGen Pharmaceuticals
- Shanghai Huaguan Biochip
- SiBiono GeneTech
- Abbott
- AstraZeneca
- Boehringer Ingelheim
- Eli Lilly
- GlaxoSmithKline
- Johnson & Johnson Medical
- Merck
- Novartis
- Pfizer
- Roche


Forecast projections and future growth rates are provided to give you a forthcoming perspective of this growing industry. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed.

What you will gain:

- An in-depth understanding of the Chinese biopharmaceutical market and it’s environment
- Current market facts, figures and product lines of key players in the industry
- An insight into how generic therapeutics will propagate the Chinese biopharmaceutical market
- Knowledge of how the Chinese pharma market will integrate into the global healthcare market
- Information on key regulatory and government policies
- Data on levels of private and publically funded biopharma studies in China
- Strategies on how to adapt and restructure current business models to this industry

This report tackles key concerns to the Chinese biopharmaceutical market such as:
- Lack of regulatory policy and legislation
- Reimbursement schemes and payers concerns
- Funding and government sponsorship issues
- International scepticism of Chinese safety and efficacy therapeutic profiles

This report will tell you if the companies mentioned are:
- Strong, competitive players
- Pooling their resources for specific growth and therapeutic areas
- Investing strategically in R&D
- Have a history of strategic M&A activity

Table Of Contents

Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities and Challenges
Pharmaceutical Industry in China to 2020: An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities and Challenges
Table of Contents
1.0 Summary 8
1.1 Objectives of Report 8
1.2 Scope of Study 9
1.3 Data Sources and Methodology 9
1.4 Key Findings and Observations 10
1.5 Executive Summary 11
1.5.1 Chronic Disease in China 11
1.5.2 Chinese Pharmaceutical Market 11
1.5.3 Government and Regulation Environment 12th Five Year Plan 12
1.5.4 Generic Medication Market and China 12
1.5.5 Novel Product Drug development 13
1.5.6 Global Pharmaceutical Companies Interest in China 13
2.0 Chronic Disease Prevalence Statistics 15
3.0 Business Environment 17
3.1 Economic Indicators, Trade Policy and Merchandise and Commercial Trade Statistics 17
3.2 Gross Domestic Product of China Analysis 19
3.3 Annual Health Expenditure in China Analysis 20
3.4 Global and Chinese Economic History 21
3.5 Chinese Economic History in Comparison to Emerging Markets and Developing Countries 22
3.6 Chinese Economic History in Comparison to Advanced Economies (US, Europe) 24
4.0 Chinese Pharmaceutical Market 29
4.1 Global Pharma Market Overview 29
4.2 China Pharma Market Overview 29
4.3 Main Players in China's Pharmaceutical Industry 32
4.3.1 Anti-Allergy Drug Market 32
4.3.2 Asthma/COPD Drug Market 33
4.3.3 Benign Prostate Hyperplasia Drug Market 34
4.3.4 Anti-Depressant Drug market 34
4.3.5 Dermatitis Drug Market 36
4.3.6 Diabetes Drug Market 37
4.3.7 Hypertension Drug Market 39
4.3.8 Dyslipidaemia Drug Market 40
4.3.9 Senile Dementia Drug Market 41
4.3.10 Cancer Drug Market 43
4.3.11 Rheumatoid Arthritis Drug Market 44
4.3.12 Ophthalmological Drug Market 45
4.3.13 Liver Disease Drug Market 46
4.3.14 Antibiotic Drug Market 47
4.3.15 Vaccine Market 48
5.0 Government and Regulation Environment 50
5.1 12th Five Year Plan 50
5.2 Intellectual Property for Pharmaceuticals in China 51
5.3 State Food and Drug Administration (SFDA) 56
5.4 Pharmaceutical Distribution Process in China 59
5.5 Multinational Company Strategy for the Essential Drug List 61
5.5.1 Expanded Coverage of Medical Conditions 61
5.5.2 A Standardized Essential Drug List 62
5.5.3 Increased EDL Use in Class 3 and Class 2 Hospitals 62
5.5.4 Increased Product Quality 62
5.6 How did Zocor Gain Access to the National Essential Drug List? 62
5.7 What are the Top Selling Agents from Multinational Companies on the Essential Drug List? 63
5.8 What Key Strategies Should be Investigated Prior to Essential Drug List Integration? 63
6.0 China - Second Largest Pharma Market 2014 65
6.1 China - At the Forefront of Emerging Markets 65
6.2 Generic Medication Market and China 65
6.3 Novel Product Drug Development 67
6.4 Drug Development Cost and Outsourcing 69
6.5 Drug Development Case Study - Beijing Continent Pharmaceuticals 70
6.6 China's Pharmaceutical Export Market 70
6.7 Spot Light - China Medical City Taizhou 72
7.0 Global Pharmaceutical Companies Interest in China 74
7.1 Abbott 74
7.1.1 AbbVie China 83
7.2 AstraZeneca China 85
7.3 Bayer China 95
7.4 Boehringer Ingelheim China 101
7.5 Eli Lilly China 106
7.6 GlaxoSmithKline China 114
7.7 Johnson and Johnson Medical China 121
7.8 Merck China 126
7.9 Novartis China 130
7.10 Novo Nordisk China 134
7.11 Pfizer China 139
7.11.1 Pfizer China RandD Centre 140
7.11.2 Pfizer China Products 141
7.11.3 Pfizer Financials 143
7.12 Roche China 146
7.13 Sanofi China 153
8.0 Chinese Pharmaceutical Companies 160
8.1 Amoytop Biotech 160
8.1.1 Overview 160
8.1.2 Active Pharmaceutical Products 162
8.2.1 Research and Development 162
8.2.2 Financial Information 162
8.3 Beijing Continent Pharmaceuticals 163
8.4 FusoGen Pharmaceuticals 163
8.4.1 Financial Information 165
8.5 Shanghai Huaguan Biochip 165
8.5.1 Financial Information 166
8.6 SiBiono GeneTech 168
8.6.1 Financial Information 169
8.7 Sinovac Biotech 169
8.7.1 Financial Information 171
8.7.2 New Products 175
8.7.3 Split Virion Pandemic Influenza Vaccine 175
8.7.4 RabEnd 176
8.7.5 Pipeline Portfolio 176
8.7.6 EV71 virus Vaccine 176
8.7.7 Pneumococcal Conjugate Vaccine 176
8.7.8 Pneumococcal Polysaccharide Vaccine 176
8.7.9 Varicella Vaccine 176
8.7.10 Measles, Mumps and Rubella Vaccines 176
8.7.11 Rotavirus Vaccine 177
9.0 Drivers, Restraints, Challenges and Opportunity Analysis 178
9.1 Key Drivers of the Pharmaceutical Market in China 178
9.2 Key Restraints of the Pharmaceutical Market in China 179
9.3 Challenges of the Pharmaceutical Industry in China 179
9.4 Opportunities Within BioPharma China 181


List of Tables

Table 2.1: Most Prominent Cancer Manifestations in China 16
Table 2.2: Top Fifty Diseases in China Today (non-cancer) 16
Table 2.3: Top Infectious Disease States in China Today 16
Table 3.1: World Trade Organisation Basic Indicators on China 17
Table 3.2: World Trade Organisation Trade Policy of China 17
Table 3.3: World Trade Organisation Merchandise Trade Statistics: China 18
Table 3.4: World Trade Organisation Commercial Services Trade Statistics: China 18
Table 3.5: Summary of International Monetary Fund Members' Quota, Reserve Position, SDR Holdings,
Outstanding Credit, Recent Lending Arrangements, Projected Payments Due and Monthly Historical
Transactions of China 19
Table 3.6: China Statistics 19
Table 4.1: Top Global Pharma Markets 2003-2013 29
Table 4.2: Major Players in China's Anti-Allergy Drug Market 33
Table 4.3: Major Players in China's Asthma Drug Market 33
Table 4.4: Major Players in China's Benign Prostate Hyperplasia (BPH) Drug Market 34
Table 4.5: Major Players in China's Anti-Depressant Drug Market 35
Table 4.6: Prescription Dermatitis Drug Industry Sub-Markets and Associated Therapeutics 36
Table 4.7: Top Prescription Dermatitis Drugs on the Chinese Market 37
Table 4.8: Major Players in China's Dermatitis Drug Market 37
Table 4.9: Major Players in China's Diabetic Drug Market 39
Table 4.10: Major Players in China's Hypertension Drug Market 40
Table 4.11: Major Players in China's Dyslipidaemia Drug Market 41
Table 4.12: Major Players in China's Senile Dementia Drug Market 42
Table 4.13: Major Players in China's Cancer Drug Market 43
Table 4.14: Major Players in China's Rheumatoid Arthritis Drug Market 45
Table 4.15: Major Players in China's Ophthalmological Drug Market 46
Table 4.16: Major Players in China's Liver Disease Drug Market 46
Table 4.17: Major Players in China's Antibiotic Drug Market 47
Table 5.1: Seven Strategic Emerging Industries of China's 12th Five Year Plan 2011-2015 50
Table 5.2: Outline of the Chinese Promotion Plan for the Implementation of the National Intellectual
Property Strategy, 2012 52
Table 5.3: Challenges facing the Pharmaceutical Distribution Business in China 59
Table 5.4: Prescription Drug Sales Distribution Channels in China 59
Table 5.5: Extra Government Guidelines for the Chinese Essential Drug System 61
Table 6.1: Major Biogeneric Products in China 66
Table 6.2: Imported Therapeutics with Administrative Protection in China 66
Table 6.3: Expired Proprietary Pharmaceuticals in China 67
Table 6.4: Reasons Why Multinational Companies Seek CMO's in China 69
Table 6.5: Comparison of Clinical Trial Cost between China and the USA 70
Table 6.6: Five Functional Districts of China Medical City 72
Table 6.7: Five Key RandD and Manufacturing Areas within China Medical City 73
Table 7.1: Top Multinational Company Performance, China 74
Table 7.2: Abbott Areas of Expertise 78
Table 7.3: Abbott Key Global Products 80
Table 7.4: AbbVie (Abbott) Speciality Care Products Holding Market-Leading Positions 80
Table 7.5: Abbott China Anaesthesia Product Profile 80
Table 7.6: Abbott China Cardiovascular Product Profile 80
Table 7.7: Abbott China Vaccine Product Profile 80
Table 7.8: Abbott China Digestion Product Profile 81
Table 7.9: Abbott China HIV Product Profile 81
Table 7.10: Abbott Rheumatology HIV Product Profile 81
Table 7.11 Abbott China Gynaecological Product Profile 81
Table 7.12 Abbott China Urological Product Profile 81
Table 7.13 Abbott China Liver Disease Product Profile 81
Table 7.14 Abbott China Diagnostic Product Profile 81
Table 7.15: Abbott China Molecular Diagnostic Product Profile 82
Table 7.16: Abbott Blood Glucose Meter Product Profile 82
Table 7.17: Abbott Cardiovascular Product Profile 83
Table 7.18: Abbott Rapid Bedside Diagnostic/ Point of Care Product Profile 83
Table 7.19: Important Milestones in AstraZeneca China's History 86
Table 7.20: AstraZeneca China Anaesthetic Range of Products 87
Table 7.21: AstraZeneca China Cardiovascular and Metabolism Range of Products 87
Table 7.22: AstraZeneca China Gastrointestinal Range of Products 87
Table 7.23: AstraZeneca China Infection Range of Products 87
Table 7.24: AstraZeneca China Neurology Range of Products 87
Table 7.25: AstraZeneca China Oncology Range of Products 88
Table 7.26: AstraZeneca China Respiratory Range of Products 88
Table 7.27: AstraZeneca Top Branded Pharmaceuticals Globally 2014 90
Table 7.28: AstraZeneca Sales (US$ Mil) of Top Branded Pharmaceuticals Globally 2010-2014 91
Table 7.29: Bayer China Important Milestones 95
Table 7.30: Therapeutic Areas Covered by Bayer Healthcare Pharmaceuticals in China 96
Table 7.31: Bayer - Leading Therapeutics in China 100
Table 7.32: Bayer Top Selling Consumer Health Products 100
Table 7.33: Bayer Key Product Patent Expiration Dates China 101
Table 7.34: Boehringer Ingelheim Major Products in China 102
Table 7.35: Main Therapeutic Areas of Interest to Boehringer Ingelheim China 102
Table 7.36: Global Therapeutic Pipeline, Boehringer Ingelheim 105
Table 7.37: Major Global Boehringer Ingelheim Therapeutic Products 105
Table 7.38: Lilly Late Stage New Molecular Entities: Indication, Geography and Developments 108
Table 7.39: Lilly New Molecular Entities Approved, Under Regulatory Review and in Clinical Trials in
the US, Japan and Europe 110
Table 7.40: Lilly Key Product by US Revenue and Patent Protection Data FY2014 111
Table 7.41: Lilly Key Product by Non-US Revenue and Patent Protection Data FY2014 111
Table 7.42: Eli Lilly Top Selling Global Branded Pharmaceuticals 2012-2013 and Percentage Change 112
Table 7.43: Lilly Top Selling Global Branded Pharmaceuticals FY2014 ($ millions) Within and
Outside the US Market 113
Table 7.44: GlaxoSmithKline Prescription Portfolio and Indications in China 114
Table 7.45: GlaxoSmithKline Vaccine Portfolio and Indications in China 115
Table 7.46: GlaxoSmithKline Over the Counter Portfolio and Indications in China 115
Table 7.47: GlaxoSmithKline Global Pharmaceutical Sales by Therapeutic Area, FY2012-2014 118
Table 7.48: GlaxoSmithKline Global Vaccine Sales FY2012-2013 120
Table 7.49: Significant Milestones in Johnson and Johnson China History 122
Table 7.50: Johnson and Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area
and Percentage Change, 2012-2014 125
Table 7.51: Merck Serono Pharmaceutical Key Therapeutic Areas in China 126
Table 7.52: Merck Serono Fertility and Infertility Therapeutic Portfolio in China 126
Table 7.53: Merck Serono Therapeutic Portfolio in China 127
Table 7.54: Merck Pharmaceutical Hong Kong Therapeutic Portfolio 127
Table 7.55: Merck Main Pharmaceutical Brand Sales Figures FY2012-FY2014 127
Table 7.56: Merck Global Pharmaceutical, Animal Health and Consumer Health Sales 2012-2013 128
Table 7.57: Merck Top Ten Global Pharmaceutical Brand Sales 2012-2013 129
Table 7.58: Range of Diabetic Products from Novo Nordisk China 135
Table 7.59: QUICKFACTs - Pfizer China 140
Table 7.60: Important Milestones - Pfizer China 140
Table 7.61: Pfizer Range of Infectious Disease Therapeutics for Chinese Health Care Market 141
Table 7.62: Pfizer Range of Mental Health Products for Chinese Health Care Market 141
Table 7.63: Pfizer Range of Genitourinary Products for Chinese Health Care Market 141
Table 7.64: Pfizer Range of Endocrine Products for Chinese Health Care Market 142
Table 7.65: Pfizer Range of Women's Health Products for Chinese Health Care Market 142
Table 7.66: Pfizer Range of Cardiovascular Disease Products for Chinese Health Care Market 142
Table 7.67: Pfizer China - Range of Oncology Products for Chinese Health Care Market 142
Table 7.68: Pfizer Key Consumer Healthcare Global Products 142
Table 7.69: Pfizer Key Speciality Care Global Products 142
Table 7.70: Pfizer Key Oncology Global Products 143
Table 7.71: Pfizer Key Global Established Products 143
Table 7.72: Pfizer Key Innovative Products in Emerging Markets 143
Table 7.73: Pfizer Key Animal Health Global Products 143
Table 7.74: Pfizer Product Sales with Significant Impact on Revenues 2013:2014 Comparison 145
Table 7.75: Roche Pharmaceuticals Product List in China 147
Table 7.76: Roche Global Sales (CHF Millions) by Therapeutic Area, 2012-2014 and Percentage
Change (CER) 150
Table 7.77: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South
Korea, Turkey, 2011-2014 and Percentage Change (CER) 151
Table 7.78: Seven Growth Platforms of Sanofi China 153
Table 7.79: Key Therapeutic Areas of Sanofi China 153
Table 8.1: Important Milestones in Amoytop Biotech's Development 160
Table 8.2: Amoytop Biotech Main Objectives of Research and Development Division 161
Table 8.3: Amoytop Biotech Panel of Recombinant Protein Therapeutics in Clinical Studies 161
Table 8.4: Amoytop Biotech Portfolio of Patented Y-Shaped Branched Pegylated Recombinant
Protein Therapeutics within Clinical Investigation in China 161
Table 8.5: Current Recombinant protein therapeutics by Amoytop Biotech 162
Table 8.6: Active Pharmaceutical Product Portfolio of Amoytop Biotech 162
Table 8.7: Milestones Achieved by FusoGen Pharmaceuticals 164
Table 8.8: Research and Development Sub-groups of FusoGen Pharmaceuticals 165
Table 8.9: Shanghai Huaguan Biochip Rapid Test Portfolio 165
Table 8.10: Shanghai Huaguan Biochip Multi Drugs of Abuse Test Profile 165
Table 8.11: Shanghai Huaguan Biochip Infectious Disease Test Portfolio 166
Table 8.12: Shanghai Huaguan Biochip Diagnostic Test Portfolio 166
Table 8.13: Shanghai Huaguan Biochip Laboratory Service Portfolio 166
Table 8.14: Intracellular Functions of the Gene Therapy Agent, Gendicine by SiBiono GeneTech 168
Table 8.15: Gendicine - Potential Oncology Indications for Future Approval 168
Table 8.16: Current Human Vaccine Portfolio of Sinovac Biotech 169
Table 8.17: Important Milestones in the History of Sinovac Biotech 170
Table 8.18: Pipeline Portfolio of Sinovac Biotech 170
Table 8.19: Total Sales Figures Sinovac Biotech 2007-2012 172
Table 9.1: Key Drivers of the Pharmaceutical Market in China 178
Table 9.2: Key Restraints of the Pharmaceutical Market in China 179
Table 9.3: Key Challenges of the Pharmaceutical Market in China 179
Table 9.4: Patent Expirations of Selected Top Brand Name Therapeutics by 2020 180
Table 9.5: Leading Pharmaceutical Areas with Significant Opportunities in China 181

List of Figures

Figure 2.1: Proportional (%) Mortality Rate of Total Deaths in China, All Ages 15
Figure 3.1: China GDP Figures 2006-2015 20
Figure 3.2: Annual Health Expenditure in China 2006-2015 20
Figure 3.3: Global, Emerging Market and Developing Countries Economic Growth Change 2010-2013 21
Figure 3.4: Global, Emerging Market and Developing Countries and China Economic Growth Change
2010-2013 22
Figure 3.5: Global, Emerging Market and Developing Countries and Russia Economic Growth Change
2010-2013 23
Figure 3.6: Global, Emerging Market and Developing Countries and India Economic Growth Change
2010-2013 23

Figure 3.7: Global, Emerging Market and Developing Countries and Brazil Economic Growth Change
2010-2013 24
Figure 3.8: Global, US and Germany Economic Growth 2010-2013 25
Figure 3.9: US and UK Gross Domestic Product per capita Forecast 2010-2017 25
Figure 3.10: Global, France and Italy Economic Growth 2010-2013 26
Figure 3.11: France, Germay and Italy Gross Domestic Product per capita Forecast 2010-2017 26
Figure 3.12: Global, UK and Spain Economic Growth 2010-2013 27
Figure 3.13: Global, Japan and Canada Economic Growth 2010-2013 27
Figure 3.14: China, Brazil and India Gross Domestic Product per capita Forecast 2010-2017 28
Figure 4.1: The Chinese Healthcare Industry by Sector 32
Figure 4.2: Global Diabetes Market, USA, Europe, Japan, RoW, 2015 38
Figure 4.3: Diabetes Market China 2009-2015 38
Figure 4.4: Global Dementia Market 2011-2017 41
Figure 4.5: Market Share of State-Owned, Privately-Owned and Foreign-Owned Enterprises in the
Chinese Vaccine Market 48
Figure 5.1: Projected Figures of Strategic Emerging Industry GDP Percentage Contribution to 2020 50
Figure 5.2: State Drug and Food Administration, China, Application and Approval Procedure for
Imported Drugs 57
Figure 5.3: State Drug and Food Administration, China, Application and Approval Procedure for
Clinical Trials 58
Figure 5.4: Revenue Share (Percentage) of Major Players in Chinese Pharmaceutical Distribution
Market 60
Figure 5.5: Revenue Share (Billion $) of Major Players in Chinese Pharmaceutical Distribution
Market 60
Figure 5.6: Number of Drugs on Essential Drug List by Western Therapeutic and Traditional Chinese
Medicine, 2009-2014 61
Figure 5.7: Sales of Merck's Zocor and its Performance After Inclusion on Essential Drug List 63
Figure 6.1: Three Tier ‘Pharmerging' Markets with Potential for Significant Growth 65
Figure 6.2: Number of Investigational New Drug Applications in China 2003-2013 67
Figure 6.3: Number of New Drug Applications in China 2003-2013 68
Figure 6.4: Current Number of Novel Therapeutics in Phase I, Phase II and Phase III Clinical Trials in
China 68
Figure 6.5: Percentage of Clinical Trial Drug by Disease State 69
Figure 6.6: China's Regional Pharmaceutical Processing Trade Export Market Share Percentage 71
Figure 6.7: Contract Amount of China's Regional Pharmaceutical Processing Trade Export 71
Figure 6.8: Top Five Contract Pharmaceutical Export Markets of China 72
Figure 7.1: Abbott Division Sales Percentage by Diagnostics, Nutrition, Medical Devices and
Established Pharmaceuticals 2014 75
Figure 7.2: Abbott Medical Device Segment Sales 2014 - Vascular, Diabetes and Vision 75
Figure 7.3: Abbott Laboratories Geographic Distribution of Revenue -USA, Established and
Emerging Markets 77
Figure 7.4: Abbott Laboratories Established and Emerging Revenue Share (%) 2012-2015 78
Figure 7.5: Abbott - Business Specialization Strategy: Diversified Medical Products and ResearchBased
Pharmaceuticals 78
Figure 7.6: Abbott Diversified Medical Product Portfolio 79
Figure 7.7: AbbVie Global Revenue 2013-2014 84
Figure 7.8: AbbVie Global, International and USA Total Revenue 2014 84
Figure 7.9: AbbVie Global, USA and International Revenue Generated 2013-2014 85
Figure 7.10: AbbVie Revenue Generated by Creon, DuoDopa and Synthroid 2013-2014 85
Figure 7.11: AstraZeneca Sales Revenue (US$ Millions) in China, FY2010-2014 89
Figure 7.12: AstraZeneca Global Revenue (Billions) by Geographic Area: USA, Europe, China,
Japan, Canada, FY2014 90
Figure 7.13: AstraZeneca Cardiovascular Product (Atacand, Crestor, Seloken/Toprol-XL) Global
Sales FY2010-2014 91
Figure 7.14: AstraZeneca Gastrointestinal Product (Nexium) Global Sales FY2010-2014 92


Figure 7.15: AstraZeneca Infection Product (Synagis) Global Sales FY2010-2014 92
Figure 7.16: AstraZeneca Neuroscience Product (Seroquel-IR, Seroquel-XR) Global Sales FY2010-2014 93
Figure 7.17: AstraZeneca Oncology Product (Zoladex) Global Sales FY2010-2014 93
Figure 7.18: AstraZeneca Respiratory/Inflammation Product (Pulmicort, Symbicort) Global Sales
2010-2012 94
Figure 7.19: Bayer Geographical Sales China, USA, Germany FY2013-2014 97
Figure 7.20: Bayer Sales Distribution by Division: Healthcare, Crop Science, Material Science FY2014 98
Figure 7.21: Bayer Healthcare Sales Breakdown: Pharmaceuticals and Consumer Health FY2014 98
Figure 7.22: Boehringer Ingelheim Global Sales by Geographic Region, Europe, Americas, Asia,
Australia, Africa FY2014 103
Figure 7.23: Boehringer Ingelheim Sales by Product Class FY2014 103
Figure 7.24: Boehringer Ingelheim Oncology Compounds in Development 106
Figure 7.25: Lilly Global Revenue FY2010-FY2014 113
Figure 7.26: GlaxoSmithKline Total Sales, Pharmaceutical, Vaccine and Consumer Healthcare Sales
2012-2014 (£ Billions) 118
Figure 7.27: GlaxoSmithKline Global Pharmaceutical Sales (£ Millions) by Therapeutic Area,
FY2012-2013 119
Figure 7.28: GlaxoSmithKline Sales by Therapeutic Area FY2014 119
Figure 7.29: GlaxoSmithKline Global Vaccine Sales, FY2012-2014 120
Figure 7.30: GlaxoSmithKline Global Sales by Geographic Region - USA, Europe, Emerging
Markets, Japan, FY2012-2014 121
Figure 7.31: Johnson and Johnson Pharmaceutical Segment Sales (US$ Billion) by Therapeutic Area,
2012-2014 125
Figure 7.32: Novartis International Sales (%) by Geographic Region, FY2013-FY2014 133
Figure 7.33: Novartis International Sales (US$ Millions) by Geographic Region, FY2012-FY2014 134
Figure 7.34: Novo Nordisk Total China Sales FY2009-FY2014 138
Figure 7.35: Novo Nordsk Total Diabetes Care Market Sales Performance (DKK Millions) China
FY2010-FY2014 138
Figure 7.36: Novo Nordisk Diabetes Care (NovoRapid/NovoLog, NovoMix/NovoLog Mix, Levemir, Modern
Insulin, Human Insulin, Victoza) Sales Performance (DKK Millions) China FY2010-FY2014 139
Figure 7.37: Business Sectors - Pfizer China 140
Figure 7.38: Roche Total Global Sales (CHF Millions) FY2012-FY2014 150
Figure 7.39: Roche Global Sales (CHF Billions) by Therapeutic Area, FY2012-FY2014 151
Figure 7.40: Roche Pharmaceutical Division Emerging Market Total Sales FY2011-FY2014 151
Figure 7.41: Roche Pharmaceutical Division Sales from Brazil, China, India, Mexico, Russia, South
Korea, Turkey, FY2012 - FY2014 152
Figure 7.42: Roche Pharmaceutical Division Sales in China FY2012-FY2014 152
Figure 7.43: Sanofi Geographic Market Share - Emerging Markets, USA and Western Europe
FY2013-FY2014 156
Figure 7.44: Sanofi Geographic Market Share (%) -China, Russia and USA 2012 156
Figure 7.45: Sanofi Global Diabetes Revenue by Brand FY2014 157
Figure 7.46: Sanofi Global Rare Disease Revenue by Brand FY2014 157
Figure 7.47: Sanofi Global Multiple Sclerosis Revenue by Brand FY2014 158
Figure 7.48: Sanofi Global Oncology Revenue by Brand FY2014 158
Figure 8.1: FusoGen Pharmaceuticals Product Pipeline and Clinical Trial Progression 164
Figure 8.2: Shanghai Huaguan Biochip Serial Analysis of Gene Expression (SAGE) Service 167
Figure 8.3: Total Sales Figures Sinovac Biotech 2007-2012 172
Figure 8.4: Percentage of Sales Attributed to Healive Vaccine, 2009-2012 173
Figure 8.5: Reported Sales of Healive Vaccine, 2009-2012 173
Figure 8.6: Reported Sales of Bilive Vaccine, 2009-2012 174
Figure 8.7: Reported Sales of Anflu Vaccine, 2009-2012 174
Figure 8.8: Reported Sales of Panflu Vaccine, 2009-2011 175

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.